

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司 *
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

**COMPLETION OF FIRST SUBJECT ENROLLMENT
IN PHASE II CLINICAL TRIAL OF GT20029 GEL
FOR TREATMENT OF ANCE IN CHINA**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest information related to the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 17 June 2024, the Company has completed the first subject enrollment in the phase II clinical trial (the “**Phase II Clinical Trial**”) in China of its in-house developed androgen receptor proteolysis targeting chimera (“**PROTAC**”) compound GT20029 for the treatment of acne. Developed by the Company’s in-house PROTAC platform, GT20029 is the first topical PROTAC compound which has entered the phase II clinical stage worldwide.

The Phase II Clinical Trial is a multi-center, randomized, double-blind, placebo-controlled study, which is designed to evaluate the efficacy, safety and pharmacokinetics of GT20029 for the treatment of acne through the adoption of GT20029 0.5% once-a-day (“**QD**”) and 1% QD as the drug-related dosage. The Phase II Clinical Trial involves a total of 10 clinical research centers in China, and Professor Xiang Leihong(項蕾紅) from Fudan University Huashan Hospital (復旦大學附屬華山醫院) is the lead principal investigator.

In November 2022 and February 2023, the Company respectively announced the positive top-line data for the phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (“**AGA**”) and acne

in China (healthy subjects) and in the U.S. (healthy subjects and subjects with AGA or acne). The data demonstrated good safety, tolerability and pharmacokinetics of GT20029 in healthy subjects and subjects with AGA or acne. For details, please refer to the announcements of the Company dated 24 November 2022 and 10 February 2023, respectively.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that GT20029 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, 17 June 2024

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*